Top

Published in:

Open Access 01-12-2017 | Research article

Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFβ2/TβR and CD44 in MDA-MB-231 breast cancer cells

Authors: Anja Reithmeier, Elena Panizza, Michael Krumpel, Lukas M. Orre, Rui M. M. Branca, Janne Lehtiö, Barbro Ek-Rylander, Göran Andersson

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

Tartrate-resistant acid phosphatase (TRAP/ACP5), a metalloenzyme that is characteristic for its expression in activated osteoclasts and in macrophages, has recently gained considerable focus as a driver of metastasis and was associated with clinically relevant parameters of cancer progression and cancer aggressiveness.

Methods

MDA-MB-231 breast cancer cells with different TRAP expression levels (overexpression and knockdown) were generated and characterized for protein expression and activity levels. Functional cell experiments, such as proliferation, migration and invasion assays were performed as well as global phosphoproteomic and proteomic analysis was conducted to connect molecular perturbations to the phenotypic changes.

Results

We identified an association between metastasis-related properties of TRAP-overexpressing MDA-MB-231 breast cancer cells and a TRAP-dependent regulation of Transforming growth factor (TGFβ) pathway proteins and Cluster of differentiation 44 (CD44). Overexpression of TRAP increased anchorage-independent and anchorage-dependent cell growth and proliferation, induced a more elongated cellular morphology and promoted cell migration and invasion. Migration was increased in the presence of the extracellular matrix (ECM) proteins osteopontin and fibronectin and the basement membrane proteins collagen IV and laminin I. TRAP-induced properties were reverted upon shRNA-mediated knockdown of TRAP or treatment with the small molecule TRAP inhibitor 5-PNA. Global phosphoproteomics and proteomics analyses identified possible substrates of TRAP phosphatase activity or signaling intermediates and outlined a TRAP-dependent regulation of proteins involved in cell adhesion and ECM organization. Upregulation of TGFβ isoform 2 (TGFβ2), TGFβ receptor type 1 (TβR1) and Mothers against decapentaplegic homolog 2 (SMAD2), as well as increased intracellular phosphorylation of CD44 were identified upon TRAP perturbation. Functional antibody-mediated blocking and chemical inhibition demonstrated that TRAP-dependent migration and proliferation is regulated via TGFβ2/TβR, whereas proliferation beyond basal levels is regulated through CD44.

Conclusion

Altogether, TRAP promotes metastasis-related cell properties in MDA-MB-231 breast cancer cells via TGFβ2/TβR and CD44, thereby identifying a potential signaling mechanism associated to TRAP action in breast cancer cells.

Available only for authorised users

Oddie GW, Schenk G, Angel NZ, Walsh N, Guddat LW, de Jersey J, et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone [Internet]. 2000;27:575–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11062342 CrossRef

Ljusberg J, Ek-Rylander B, Andersson G. Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. Biochem J [Internet]. 1999;343 Pt 1:63–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1220524&tool=pmcentrez&rendertype=abstract CrossRef

Uppenberg J, Lindqvist F, Svensson C, Ek-Rylander B, Andersson G. Crystal structure of a mammalian purple acid phosphatase. J Mol Biol. 1999;290:201–11.CrossRefPubMed

Ek-Rylander B, Bill P, Norgård M, Nilsson S, Andersson G. Cloning, sequence, and developmental expression of a type 5, tartrate-resistant, acid phosphatase of rat bone. J Biol Chem [Internet]. 1991;266:24684–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1722212

Lord DK, Cross NC, Bevilacqua MA, Rider SH, Gorman PA, Groves AV, et al. Type 5 acid phosphatase. Sequence, expression and chromosomal localization of a differentiation-associated protein of the human macrophage. Eur J Biochem [Internet]. 1990; [cited 2015 Oct 18];189:287–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2338077

Hayman AR, Dryden AJ, Chambers TJ, Warburton MJ. Tartrate-resistant acid phosphatase from human osteoclastomas is translated as a single polypeptide. Biochem. J. [Internet]. 1991;277(Pt 3):631–4. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1151288&tool=pmcentrez&rendertype=abstract CrossRef

Ling P, Roberts RM. Uteroferrin and intracellular tartrate-resistant acid phosphatases are the products of the same gene. J. Biol. Chem. [Internet]. 1993; [cited 2015 Oct 18];268:6896–902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8463220

Ek-Rylander B, Andersson G. Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res. 2010;316:443–51. Elsevier B.V.CrossRefPubMed

An J, Briggs TA, Dumax-Vorzet A, Alarcón-Riquelme ME, Belot A, Beresford M, et al. Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016; [cited 2016 Jul 22]; (Hoboken, N.J.) [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27390188

10.

Andersson G, Ek-Rylander B, Hollberg K, Ljusberg-SjöLander J, Lång P, Norgård M, et al. TRACP as an Osteopontin Phosphatase. J Bone Miner Res [Internet]. 2003;18:1912–5. [cited 2017 Apr 4]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/14584906 CrossRef

11.

Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, De Laet C, et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet [Internet]. 2011;43:132–7. [cited 2011 Sep 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21217752 CrossRef

12.

Capeller B, Caffier H, Sütterlin MW, Dietl J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res [Internet]. 2003;23:1011–5. [cited 2015 Oct 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/12820340

13.

Chao TY, Wu YY, Janckila AJ. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chim Acta. 2010;411:1553–64. Elsevier B.V.CrossRefPubMed

14.

Lyubimova NV, Pashkov MV, Tyulyandin SA, Gol’dberg VE, Kushlinskii NE. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med. 2004;138:77–9.CrossRefPubMed

15.

Tauchert S, di Liberto A, Cordes T, Thill M, Salehin D, Friedrich M. Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases. Clin Exp Obs Gynecol [Internet]. 2009;36:219–25. [cited 2011 Nov 28]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/20101852

16.

Yao NS, Wu YY, Janckila AJ, Ku CH, Hsieh AT, Ho CL, et al. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clin Chim Acta. 2011;412:181–5. Elsevier B.V.CrossRefPubMed

17.

Adams LM, Warburton MJ, Hayman AR. Human breast cancer cell lines and tissues express tartrate-resistant acid phosphatase (TRAP). Cell Biol Int. 2007;31:191–5.CrossRefPubMed

18.

Honig A, Rieger L, Kapp M, Krockenberger M, Eck M, Dietl J, et al. Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study. BMC Cancer [Internet]. 2006;6:199. [cited 2015 Oct 20]; Available from: http://www.biomedcentral.com/1471-2407/6/199 CrossRef

19.

Zenger S, He W, Ek-Rylander B, Vassiliou D, Wedin R, Bauer H, et al. Differential expression of tartrate-resistant acid phosphatase isoforms 5a and 5b by tumor and stromal cells in human metastatic bone disease. Clin Exp Metastasis [Internet]. 2011;28:65–73. [cited 2011 Sep 8]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/20967488 CrossRef

20.

Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, et al. Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes. Cancer Cell [Internet]. 2011;20:92–103. [cited 2015 Oct 22]; Available from: http://www.sciencedirect.com/science/article/pii/S1535610811001954 CrossRef

21.

Xia L, Huang W, Tian D, Chen Z, Zhang L, Li Y, et al. ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Oncogene [Internet]. 2014;33:1395–406. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23604121 CrossRef

22.

Kawamura M, Tanaka K, Toiyama Y, Okugawa Y, Okigami M, Yasuda H, et al. Clinical significance of tartrate-resistant acid phosphatase type-5 expression in human gastric cancer. Anticancer Res. [Internet]. 2014;34:3425–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24982350

23.

Gao Y-L, Liu M-R, Yang S-X, Dong Y-J, Tan X-F. Prognostic significance of ACP5 expression in patients with lung adenocarcinoma. Clin Respir J [Internet]. 2017 [cited 2017 Apr 18]; Available from: http://doi.wiley.com/10.1111/crj.12637

24.

Sheu T-J, Schwarz EM, Martinez DA, O’Keefe RJ, Rosier RN, Zuscik MJ, et al. A phage display technique identifies a novel regulator of cell differentiation. J. Biol. Chem. [Internet]. 2003;278:438–43. American Society for Biochemistry and Molecular Biology; [cited 2015 Oct 23]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/12403789 CrossRef

25.

Metz-Estrella D, Jonason JH, Sheu TJ, Mroczek-Johnston RM, Puzas JE. TRIP-1: A regulator of osteoblast function. J Bone Miner Res [Internet]. 2012;27:1576–84. [cited 2017 Jan 24];Available from: http://www.ncbi.nlm.nih.gov/pubmed/22460930 CrossRef

26.

Patlaka C, Mai HA, Lång P, Andersson G. The growth factor-like adipokine tartrate-resistant acid phosphatase 5a interacts with the rod G3 domain of adipocyte-produced nidogen-2. Biochem Biophys Res Commun. 2014;454:446–52.CrossRefPubMed

27.

Akhurst RJ, Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol [Internet]. 2001;11:S44–51. [cited 2016 Jun 8]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/11684442

28.

Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. [Internet]. 2001;29:117–29. Nature Publishing Group; [cited 2016 Jun 8]; Available from: http://www.nature.com/doifinder/10.1038/ng1001-117 CrossRef

29.

de Caestecker MP. Role of Transforming Growth Factor-beta Signaling in Cancer. J Natl Cancer Inst [Internet]. 2000;92:1388–402. [cited 2016 Jun 8]; Available from: http://jnci.oxfordjournals.org/content/92/17/1388.full

30.

Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. [Internet] Nature. 1994:341–7. [cited 2016 Jun 8] Available from: http://www.nature.com/doifinder/10.1038/370341a0

31.

Huang F, Chen Y-G. Regulation of TGF-β receptor activity. Cell Biosci [Internet]. 2012;2:9. [cited 2016 Jun 8]; Available from: http://www.cellandbioscience.com/content/2/1/9 CrossRef

32.

Massagué J. TGFβ Signal Transduction. Annu Rev Biochem [Internet]. 1998;67:753–91. [cited 2016 Jun 8]; Available from: http://www.annualreviews.org/doi/abs/10.1146/annurev.biochem.67.1.753 CrossRef

33.

Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb Perspect Biol [Internet]. 2016;8:a021873. [cited 2016 May 17]; Available from: http://cshperspectives.cshlp.org/content/8/5/a021873.long CrossRef

34.

Wrighton KH, Lin X, Feng X-H. Phospho-control of TGF-beta superfamily signaling. Cell Res [Internet]. 2009;19:8–20. [cited 2016 Jun 8]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2929013&tool=pmcentrez&rendertype=abstract CrossRef

35.

MacCallum J, Bartlett JMS, Thompson AM, Keen JC, Dixon JM, Miller WR. Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer [Internet]. 1994;69:1006–9. [cited 2016 Jun 10]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969445/?tool=pmcentrez&report=abstract

36.

Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer [Internet]. 1992;28:641–4. [cited 2016 Jun 10]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/1317202 CrossRef

37.

Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res [Internet]. 1992;52:6949–52. [cited 2016 Jun 10];Available from: http://www.ncbi.nlm.nih.gov/pubmed/1458485

38.

Dave H, Trivedi S, Shah M, Shukla S. Transforming growth factor beta 2: a predictive marker for breast cancer. Indian J Exp Biol [Internet]. 2011;49:879–87. [cited 2016 Nov 25]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22126020

39.

Rodón L, Gonzàlez-Juncà A, Del Mar IM, Sala-Hojman A, Martínez-Sáez E, Seoane J. Active CREB1 promotes a malignant TGFb2 autocrine loop in glioblastoma. Cancer Discov [Internet]. 2014;4:1230–41. [cited 2016 Nov 4];Available from: http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159-8290.CD-14-0275 CrossRef

40.

Bourguignon LYW, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J. Biol. Chem. [Internet]. 2002;277:39703–12. [cited 2017 Mar 2]; Available from: http://www.jbc.org/cgi/content/short/277/42/39703

41.

Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1). Science (80-. ). [Internet]. 1996;271:509–12. Available from: http://science.sciencemag.org/content/271/5248/509

42.

Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J. Biol. Chem. [Internet]. 1994;269:14853–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8195113

43.

Franzén A, Heinegård D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. [Internet]. 1985;232:715–24. [cited 2015 Oct 15]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1152943&tool=pmcentrez&rendertype=abstract CrossRef

44.

Ek-Rylander B, Barkhem T, Ljusberg J, Ohman L, Andersson KK, Andersson G. Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase. Biochem. J. [Internet]. 1997;321(2):305–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1218069/?tool=pmcentrez

45.

Krumpel M, Reithmeier A, Senge T, Baeumler TA, Frank M, Nyholm PG, et al. The small chemical enzyme inhibitor 5-phenylnicotinic acid/CD13 inhibits cell migration and invasion of tartrate-resistant acid phosphatase/ACP5-overexpressing MDA-MB-231 breast cancer cells. Exp Cell Res [Internet]. 2015;339:154–62. [cited 2015 Oct 13]; Available from: http://www.sciencedirect.com/science/article/pii/S0014482715301014 CrossRef

46.

Zenger S, Ek-Rylander B, Andersson G. Biogenesis of tartrate-resistant acid phosphatase isoforms 5a and 5b in stably transfected MDA-MB-231 breast cancer epithelial cells. Biochim Biophys Acta - Mol Cell Res. 2010;1803:598–607. Elsevier B.V.;CrossRef

47.

Branca RMM, Orre LM, Johansson HJ, Granholm V, Huss M, Pérez-Bercoff Å, et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat Methods [Internet]. 2014;11:59–62. Available from: http://www.nature.com/doifinder/10.1038/nmeth.2732 CrossRef

48.

Muller JW. Possible advantages of a robust evaluation of comparisons. J Res Natl Inst Stand Technol [Internet]. 2000;105:551. [cited 2016 Dec 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27551622 CrossRef

49.

Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling. Science (80-. ). [Internet]. 2011;332:1317–22. [cited 2016 Dec 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21659604 CrossRef

50.

Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The Protein Kinase Complement of the Human Genome. Science (80-. ). [Internet]. 2002;298:1912–34. Available from: http://www.sciencemag.org/content/298/5600/1912.abstract CrossRef

51.

Duan G, Li X, Köhn M. The human DEPhOsphorylation database DEPOD: A 2015 update. Nucleic Acids Res. 2015;43:D531–5.CrossRefPubMed

52.

Barrera LA, Vedenko A, Kurland JV, Rogers JM, Gisselbrecht SS, Rossin EJ, et al. Survey of variation in human transcription factors reveals prevalent DNA binding changes. Science (80-. ). [Internet]. 2016;351:1450–4. [cited 2017 Apr 4]; Available from: http://science.sciencemag.org/content/351/6280/1450 CrossRef

53.

Chen H-F, Wang J-K. The databases of transcription factors. Yi Chuan. 2010;32:1009–17.CrossRefPubMed

54.

Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nat Rev Genet. 2009;10:252–63.CrossRefPubMed

55.

Gao T, Liu Z, Wang Y, Cheng H, Yang Q, Guo A, et al. UUCD: A family-based database of ubiquitin and ubiquitin-like conjugation. Nucleic Acids Res. [Internet]. 2013;41. Available from: http://uucd.biocuckoo.org/

56.

Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512–20.CrossRefPubMed

57.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res [Internet]. 2015;43:D447–52. [cited 2016 Aug 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25352553 CrossRef

58.

Panizza E, Branca RMM, Oliviusson P, Orre LM, Lehtiö J. Isoelectric point-based fractionation by HiRIEF coupled to LC-MS allows for in-depth quantitative analysis of the phosphoproteome. Sci Rep. 2017;7:4513.CrossRefPubMedPubMedCentral

59.

Feder D, Hussein WM, Clayton DJ, Kan MW, Schenk G, McGeary RP, et al. Identification of Purple Acid Phosphatase Inhibitors by Fragment-Based Screening: Promising New Leads for Osteoporosis Therapeutics. Chem Biol Drug Des. 2012;80:665–74.CrossRefPubMed

60.

Bazer FW, Worthington-White D, Fliss MF, Gross S. Uteroferrin: a progesterone-induced hematopoietic growth factor of uterine origin. Exp Hematol [Internet]. 1991;19:910–5. [cited 2015 Oct 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/1893968

61.

Simpson KJ, Selfors LM, Bui J, Reynolds A, Leake D, Khvorova A, et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol [Internet]. 2008;10:1027–38. [cited 2011 Jul 5]; Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19160483 CrossRef

62.

Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet [Internet]. 2011;43:127–31. [cited 2017 Sept 4]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21217755

63.

Chellaiah M, Hruska K. The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int [Internet]. 2003;72:197–205. [cited 2011 Oct 4]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/12469249 CrossRef

64.

Böttinger EP, Jakubczak JL, Roberts ISD, Mumy M, Hemmati P, Bagnall K, et al. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J [Internet]. 1997;16:2621–33. EMBO Press; [cited 2016 Jun 9];Available from: http://emboj.embopress.org/cgi/doi/10.1093/emboj/16.10.2621 CrossRef

65.

Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia [Internet]. 2005;7:509–21. [cited 2016 Mar 8]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1501161&tool=pmcentrez&rendertype=abstract CrossRef

66.

Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A [Internet]. 1997;94:10669–74. [cited 2016 Jun 8]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC23442/

67.

Morton DM, Barrack ER. Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res [Internet]. 1995;55:2596–602. [cited 2016 Jun 8]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/7780974

68.

Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, et al. Transforming growth factor-beta1 enhances the invasiveness of human MDA- MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer. Wiley Subscription Services, Inc., A Wiley Company; 1998;75:721–30.

69.

Oft M, Heider K-H, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol [Internet]. 1998;8:1243–52. [cited 2016 Jun 8]; Available from: http://www.cell.com/article/S0960982207005337/fulltext CrossRef

70.

Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, et al. CD44s regulates the TGFbeta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. [Internet]. 2012;72:3414–23. American Association for Cancer Research; [cited 2016 Jul 25]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22552294 CrossRef

71.

Ouhtit A, Madani S, Gupta I, Shanmuganathan S, Abdraboh ME, Al-Riyami H, et al. TGFbeta2: A novel target of CD44-promoted breast cancer invasion. J Cancer [Internet]. 2013;4:566–72. [cited 2016 Apr 7]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3753531&tool=pmcentrez&rendertype=abstract CrossRef

72.

Zhang Y, Tripathi V, Sixt K, Heller M. TGF-beta Regulates Alternative Splicing of CD44 by Inducing Smad3 Binding to CD44 pre-mRNA. FASEB J [Internet]. 2015;29:562.15. [cited 2016 Apr 7]; Available from: http://www.fasebj.org/cgi/content/long/29/1_Supplement/562.15

Title: Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFβ2/TβR and CD44 in MDA-MB-231 breast cancer cells
Authors: Anja Reithmeier
Elena Panizza
Michael Krumpel
Lukas M. Orre
Rui M. M. Branca
Janne Lehtiö
Barbro Ek-Rylander
Göran Andersson
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3616-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma

Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer

The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer